These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 31978354)

  • 41. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial.
    McAllister L; Anderson J; Werth K; Cho I; Copeland K; Le Cam Bouveret N; Plant D; Mendelman PM; Cobb DK
    Lancet; 2014 Aug; 384(9944):674-81. PubMed ID: 24881803
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.
    Shinde V; Cho I; Plested JS; Agrawal S; Fiske J; Cai R; Zhou H; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou B; Lewis M; Price-Abbott P; Patel N; Massare MJ; Smith G; Keech C; Fries L; Glenn GM
    Lancet Infect Dis; 2022 Jan; 22(1):73-84. PubMed ID: 34563277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial.
    Steinhoff MC; Katz J; Englund JA; Khatry SK; Shrestha L; Kuypers J; Stewart L; Mullany LC; Chu HY; LeClerq SC; Kozuki N; McNeal M; Reedy AM; Tielsch JM
    Lancet Infect Dis; 2017 Sep; 17(9):981-989. PubMed ID: 28522338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and efficacy of the monovalent, trivalent and quadrivalent intranasal live attenuated influenza vaccines containing different pdmH1N1 strains.
    Yeolekar LR; Ganguly M; Tyagi P; Ingle NB; Stittelaar KJ; Waal L; Scorza FB; Mahmood K; Dhere RM
    Vaccine; 2018 Nov; 36(46):6944-6952. PubMed ID: 30322745
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.
    Mallory RM; Malkin E; Ambrose CS; Bellamy T; Shi L; Yi T; Jones T; Kemble G; Dubovsky F
    PLoS One; 2010 Oct; 5(10):e13755. PubMed ID: 21060780
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.
    Vajo Z; Tamas F; Sinka L; Jankovics I
    Lancet; 2010 Jan; 375(9708):49-55. PubMed ID: 20018367
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
    Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A double-blind trial of a new inactivated, trivalent, intra-nasal anti-influenza vaccine in general practice: relationship between immunogenicity and respiratory morbidity over the winter of 1997-98.
    Kiderman A; Furst A; Stewart B; Greenbaum E; Morag A; Zakay-Rones Z
    J Clin Virol; 2001 Feb; 20(3):155-61. PubMed ID: 11166665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human influenza virus challenge identifies cellular correlates of protection for oral vaccination.
    McIlwain DR; Chen H; Rahil Z; Bidoki NH; Jiang S; Bjornson Z; Kolhatkar NS; Martinez CJ; Gaudillière B; Hedou J; Mukherjee N; Schürch CM; Trejo A; Affrime M; Bock B; Kim K; Liebowitz D; Aghaeepour N; Tucker SN; Nolan GP
    Cell Host Microbe; 2021 Dec; 29(12):1828-1837.e5. PubMed ID: 34784508
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.
    Low JG; Lee LS; Ooi EE; Ethirajulu K; Yeo P; Matter A; Connolly JE; Skibinski DA; Saudan P; Bachmann M; Hanson BJ; Lu Q; Maurer-Stroh S; Lim S; Novotny-Diermayr V
    Vaccine; 2014 Sep; 32(39):5041-8. PubMed ID: 25045806
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.
    Jahnmatz M; Richert L; Al-Tawil N; Storsaeter J; Colin C; Bauduin C; Thalen M; Solovay K; Rubin K; Mielcarek N; Thorstensson R; Locht C;
    Lancet Infect Dis; 2020 Nov; 20(11):1290-1301. PubMed ID: 32687804
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.
    Sagara I; Healy SA; Assadou MH; Gabriel EE; Kone M; Sissoko K; Tembine I; Guindo MA; Doucoure M; Niaré K; Dolo A; Rausch KM; Narum DL; Jones DL; MacDonald NJ; Zhu D; Mohan R; Muratova O; Baber I; Coulibaly MB; Fay MP; Anderson C; Wu Y; Traore SF; Doumbo OK; Duffy PE
    Lancet Infect Dis; 2018 Sep; 18(9):969-982. PubMed ID: 30061051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
    J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
    Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
    Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial.
    Treanor JJ; Schiff GM; Hayden FG; Brady RC; Hay CM; Meyer AL; Holden-Wiltse J; Liang H; Gilbert A; Cox M
    JAMA; 2007 Apr; 297(14):1577-82. PubMed ID: 17426277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP; Robertson CA; Talbot HK; Decker MD
    Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.
    Goel G; King T; Daveson AJ; Andrews JM; Krishnarajah J; Krause R; Brown GJE; Fogel R; Barish CF; Epstein R; Kinney TP; Miner PB; Tye-Din JA; Girardin A; Taavela J; Popp A; Sidney J; Mäki M; Goldstein KE; Griffin PH; Wang S; Dzuris JL; Williams LJ; Sette A; Xavier RJ; Sollid LM; Jabri B; Anderson RP
    Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):479-493. PubMed ID: 28506538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
    Modjarrad K; Roberts CC; Mills KT; Castellano AR; Paolino K; Muthumani K; Reuschel EL; Robb ML; Racine T; Oh MD; Lamarre C; Zaidi FI; Boyer J; Kudchodkar SB; Jeong M; Darden JM; Park YK; Scott PT; Remigio C; Parikh AP; Wise MC; Patel A; Duperret EK; Kim KY; Choi H; White S; Bagarazzi M; May JM; Kane D; Lee H; Kobinger G; Michael NL; Weiner DB; Thomas SJ; Maslow JN
    Lancet Infect Dis; 2019 Sep; 19(9):1013-1022. PubMed ID: 31351922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
    Ella R; Reddy S; Blackwelder W; Potdar V; Yadav P; Sarangi V; Aileni VK; Kanungo S; Rai S; Reddy P; Verma S; Singh C; Redkar S; Mohapatra S; Pandey A; Ranganadin P; Gumashta R; Multani M; Mohammad S; Bhatt P; Kumari L; Sapkal G; Gupta N; Abraham P; Panda S; Prasad S; Bhargava B; Ella K; Vadrevu KM;
    Lancet; 2021 Dec; 398(10317):2173-2184. PubMed ID: 34774196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.